I suppose a positive for CYDY regarding the good results with mavrilimumab is that another "mab" drug is working and this supports the anti inflammatory approach to helping COVID patients. So, while this represents competition, it also adds confidence for success in the ongoing leronlimab trials.

Rubraquercus, I would be grateful for your take on this news.

Thanks.